Currently, the outcomes of conventional chemotherapeutic approaches are unsatisfactory.
Clinical application of nanoparticles seems promising. We aim to evaluate the possible …

The management of hepatocellular carcinoma (HCC) is based on a multidisciplinary
decision tree. Treatment includes loco-regional therapy, mainly transarterial …

Background Worldwide, consistent survival benefit for chemotherapy in hepatocellular
carcinoma (HCC) is a golden goal for concerned researchers. Nexavar®(sorafenib) is the …

Objectives Angiopoietins have been found to play essential roles in tumor angiogenesis.
The present study was aimed at investigating the diagnostic and prognostic values of serum …

Objectives We have confirmed the diagnostic value of protein induced by vitamin K absence
or antagonist-II (PIVKA-II) in a French cohort of patients with hepatocellular carcinoma …

Background Transarterial chemoembolization (TACE) and sorafenib are the therapeutic
standard for intermediate and advanced stage hepatocellular carcinoma (HCC) patients …

The present study investigates the in vitro cytotoxic efficacy of polymer encapsulated bare
and Mn-doped ZnO nanoparticles against human liver carcinoma Huh7 cell lines. PEG …

Background: Sorafenib is the currently recommended therapy in patients with advanced
hepatocellular carcinoma (HCC). Among the several biomarkers available for the evaluation …

Background: Hepatocellular carcinoma (HCC) is one of most common cancers with a high
mortality rate. HBV/HCV infection is an important risk factor to trigger HCC. Therefore …

Background: Hepatocellular carcinoma (HCC) is the most common type of liver
malignancies. Yet, the outcome of the traditional chemotherapeutic agents in the …